What is the process for registering a company with the FDA?

Registering a company with the FDA is not a single, one-time event but an ongoing process of compliance that depends entirely on the type of product you intend to market. The FDA does not “register companies” in a general sense; instead, it regulates specific products and the facilities that manufacture, process, pack, or store them. The core process involves three main pillars: facility registration, product listing, and achieving marketing authorization for your specific product through a pathway like a Premarket Notification (510(k)), Premarket Approval (PMA), or others. The specific requirements, timelines, and costs can vary dramatically between a dietary supplement, a medical device, or a new drug.

Understanding the FDA’s Regulatory Scope

Before diving into the steps, it’s critical to understand what the FDA regulates. It oversees human drugs, biologics, medical devices, food (including animal feed), dietary supplements, cosmetics, and electronic products that emit radiation. It does not regulate industries like clothing, real estate, or general software development. The moment you decide to sell a product in one of these regulated categories, you trigger a relationship with the FDA. The first step is always to correctly classify your product, as this determines the entire regulatory pathway. For instance, a simple tongue depressor is a medical device, but it is in a lower-risk class than a pacemaker, and the requirements for each are worlds apart. Many entrepreneurs find the initial classification daunting, which is why consulting with regulatory experts or legal counsel specializing in FDA law is a prudent first move. For foundational business structuring, such as forming the legal entity that will interact with the FDA, many find value in services specializing in 美国公司注册 to ensure their corporate foundation is solid before engaging with federal agencies.

The Universal First Steps: Facility Registration and FEI Number

For most product categories, the first mandatory action is to register your manufacturing facility. This is done through the FDA’s Unified Registration and Listing System (FURLS). This registration must be renewed annually between October 1st and December 31st. It’s important to note that facility registration does not imply FDA approval of the facility or its products; it simply informs the agency of your location and operations.

During this registration, you will receive a unique identifier known as the Facility Establishment Identifier (FEI). This number is used to track inspections and compliance activities. The following table outlines the facility registration requirements for key product types:

Product-Specific Pathways to Market

This is where the process becomes highly specialized. Getting your product listed in the FDA’s database is one thing; getting permission to legally market it is another.

Medical Devices: Class I, II, and III

Medical devices are categorized into three classes based on risk. Class I devices (e.g., bandages, examination gloves) are low-risk and typically only require facility registration and product listing. Most Class II devices (e.g., blood pressure cuffs, surgical needles) require a Premarket Notification, commonly known as a 510(k). This is a submission demonstrating that your device is “substantially equivalent” to a device already legally marketed (a “predicate device”).

The 510(k) process is data-intensive. It often requires detailed technical specifications, biocompatibility testing, sterilization validation, and performance testing data. The FDA’s goal is to review this submission within 90 days, but in reality, the “clock” stops each time the FDA asks a question, leading to an average total time of around 6 months. The user fee for a standard 510(k) in Fiscal Year 2024 is $21,760.

Class III devices (e.g., pacemakers, implantable prosthetics) are high-risk and sustain or support life. These require a Premarket Approval (PMA), which is the most stringent type of application. A PMA requires valid scientific evidence demonstrating “reasonable assurance” of the device’s safety and effectiveness, which almost always includes extensive clinical trial data. The PMA process is long and expensive, often taking several years and costing millions of dollars in research and FDA user fees (over $500,000).

Drugs and Biologics: The Most Stringent Path

The pathway for a new drug is even more rigorous. It begins with preclinical research, followed by an Investigational New Drug (IND) application to the FDA to request permission to start clinical trials in humans. Clinical trials are conducted in three phases, involving progressively larger groups of patients to assess safety and efficacy. Only after successful completion of all phases can a company submit a New Drug Application (NDA) or, for biologics, a Biologics License Application (BLA).

The entire process from lab to market for a new drug can take 10-15 years and cost over $1 billion. The NDA/BLA itself is a massive document, often comprising hundreds of thousands of pages of data. The FDA’s goal is to review a standard NDA within 10 months, but this timeline can be longer for complex applications.

Dietary Supplements: A Post-Market Surveillance Model

Dietary supplements operate under a different framework. Unlike drugs, they do not require premarket approval. Instead, the company is responsible for ensuring its products are safe and that any claims on the label are truthful and not misleading. The key steps are:

1. Facility Registration: Register your manufacturing facility with the FDA.
2. Product Listing: List your products with the FDA.
3. New Dietary Ingredient (NDI) Notification: If your supplement contains a new dietary ingredient (one not marketed in the US before 1994), you must submit an NDI notification to the FDA at least 75 days before marketing. This notification must contain evidence demonstrating a “reasonable expectation of safety.”
4. GMP Compliance: Manufacture your products in compliance with Good Manufacturing Practices (21 CFR Part 111), which cover everything from ingredient identity testing to recordkeeping.

The FDA’s role is primarily post-market. If a supplement is found to be adulterated (unsafe) or misbranded (with false claims), the FDA can take action to remove it from the market.

The Critical Role of Quality Systems

For device and drug manufacturers, facility registration is just the beginning. Maintaining ongoing compliance is governed by Quality System Regulations (QSR), also known as Good Manufacturing Practices (GMP). For devices, this is 21 CFR Part 820. It requires a comprehensive system for design controls, document control, corrective and preventive actions (CAPA), and management review. The FDA conducts routine and “for-cause” inspections of registered facilities to assess compliance with these regulations. Failure to comply can lead to warning letters, product seizures, injunctions, and even criminal prosecution.

Navigating the Financial and Timely Realities

Understanding the financial commitment is crucial. Beyond the FDA user fees, companies must budget for internal staff or external consultants, legal counsel, laboratory testing, and, for drugs and high-risk devices, clinical trials. The following table provides a high-level comparison of the key pathways:

*Timelines are highly variable and depend on product complexity, data quality, and FDA interaction.

Successfully navigating the FDA’s regulatory landscape requires a clear strategy, meticulous attention to detail, and a deep understanding of the specific rules for your product. It is a marathon, not a sprint, and building a team with the right expertise from the outset is the single most important factor in achieving a successful outcome.